JP2012504551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504551A5 JP2012504551A5 JP2011514137A JP2011514137A JP2012504551A5 JP 2012504551 A5 JP2012504551 A5 JP 2012504551A5 JP 2011514137 A JP2011514137 A JP 2011514137A JP 2011514137 A JP2011514137 A JP 2011514137A JP 2012504551 A5 JP2012504551 A5 JP 2012504551A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- dosage form
- pharmaceutical dosage
- unit
- form according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 23
- 239000002552 dosage form Substances 0.000 claims 15
- 239000011159 matrix material Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 229920006037 cross link polymer Polymers 0.000 claims 4
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 210000004051 gastric juice Anatomy 0.000 claims 3
- 239000001814 pectin Substances 0.000 claims 3
- 235000010987 pectin Nutrition 0.000 claims 3
- 229920001277 pectin Polymers 0.000 claims 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 239000000227 bioadhesive Substances 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000004584 polyacrylic acid Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 238000005187 foaming Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims 1
- 229960000564 nitrofurantoin Drugs 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200710997 | 2008-06-19 | ||
| ZA2007/10997 | 2008-06-19 | ||
| PCT/IB2009/005828 WO2009153632A1 (en) | 2008-06-19 | 2009-06-03 | A gastroretentive pharmaceutical dosage form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504551A JP2012504551A (ja) | 2012-02-23 |
| JP2012504551A5 true JP2012504551A5 (enExample) | 2012-09-06 |
| JP5560268B2 JP5560268B2 (ja) | 2014-07-23 |
Family
ID=44309136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514137A Expired - Fee Related JP5560268B2 (ja) | 2008-06-19 | 2009-06-03 | 胃保持型医薬剤形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8778396B2 (enExample) |
| EP (1) | EP2306983A1 (enExample) |
| JP (1) | JP5560268B2 (enExample) |
| WO (1) | WO2009153632A1 (enExample) |
| ZA (1) | ZA200903854B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0914080A2 (pt) * | 2008-10-08 | 2015-10-27 | Bioplus Life Sciences Pvt Ltda | "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo" |
| WO2011053917A2 (en) * | 2009-11-01 | 2011-05-05 | Adeona Pharmaceuticals, Inc. | Gastroretentive oral high dose zinc preparations |
| EP2444064A1 (en) * | 2010-10-22 | 2012-04-25 | Meliatys | Process for making multiparticulate gastroretentive dosage forms |
| US8589775B2 (en) * | 2011-03-14 | 2013-11-19 | Infineon Technologies Ag | Error tolerant flip-flops |
| CN104666267B (zh) * | 2015-03-27 | 2017-08-08 | 康普药业股份有限公司 | 一种阿昔洛韦药物组合物 |
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| JP7418958B2 (ja) * | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
| EP4534527A3 (en) | 2017-09-20 | 2025-06-18 | Thiogenesis Therapeutics, Inc. | Methods for the treatment of cysteamine sensitive disorders |
| WO2019126215A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| IL275444B2 (en) * | 2017-12-18 | 2025-01-01 | Tris Pharma Inc | Modified release drug powder formulation containing gastric-retaining raft-forming systems with pulsed drug release |
| US10835489B2 (en) | 2018-03-09 | 2020-11-17 | University Of Saskatchewan | Modified release formulations of mycophenolate mofetil |
| CN112469400A (zh) * | 2018-06-19 | 2021-03-09 | 新加坡国立大学 | 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂 |
| CN109925289B (zh) * | 2019-04-11 | 2021-05-25 | 海南普利制药股份有限公司 | 地氯雷他定分散片 |
| EP3968980A1 (en) | 2019-05-14 | 2022-03-23 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
| US12409163B2 (en) | 2021-07-30 | 2025-09-09 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-HTP) exposure |
| MX2024001390A (es) | 2021-07-30 | 2024-05-17 | Evecxia Therapeutics Inc | Formas de dosificacion gastrorretentivas de 5-hidroxitriptofano. |
| WO2023064598A1 (en) | 2021-10-14 | 2023-04-20 | Evecxia Therapeutics, Inc. | A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| TR200100731T2 (tr) * | 1998-09-14 | 2001-06-21 | Ranbaxy Laboratories Limited | Geçici ve aralıklı kontrol sağlayan, oral yoldan kontrollü ilaç verme sistemi |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US20050064027A1 (en) * | 2001-12-15 | 2005-03-24 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
| JP2004002320A (ja) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | 生体内で相転移する液状マトリックスおよび液状経口製剤 |
| EP1750717B1 (en) | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| EP1729741A2 (en) | 2004-03-03 | 2006-12-13 | Spherics, Inc. | Polymeric drug delivery system for hydrophobic drugs |
| BRPI0612594A2 (pt) * | 2005-06-29 | 2010-11-23 | Panacea Biotec Ltd | composições farmacêuticas de liberação modificada e processo de pereparação das mesmas |
| WO2007106957A1 (en) * | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
| US20080268045A1 (en) * | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
-
2009
- 2009-05-29 ZA ZA2009/03854A patent/ZA200903854B/en unknown
- 2009-06-03 EP EP09766174A patent/EP2306983A1/en not_active Withdrawn
- 2009-06-03 WO PCT/IB2009/005828 patent/WO2009153632A1/en not_active Ceased
- 2009-06-03 US US12/999,914 patent/US8778396B2/en not_active Expired - Fee Related
- 2009-06-03 JP JP2011514137A patent/JP5560268B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504551A5 (enExample) | ||
| JP2013544259A5 (enExample) | ||
| Prinderre et al. | Advances in gastro retentive drug-delivery systems | |
| CA2828747C (en) | Porous disintegratable solid substrate for personal health care applications | |
| JP5534004B2 (ja) | 口腔内崩壊錠 | |
| JP2011037876A5 (enExample) | ||
| JP2013512250A5 (enExample) | ||
| JP2003514845A (ja) | 胃内滞留性制御放出医薬剤形 | |
| JP2003514845A5 (enExample) | ||
| WO2008062440A2 (en) | Programmable buoyant delivery technology | |
| TW201127375A (en) | Taste masked topiramate composition and an orally disintegrating tablet comprising the same | |
| JPWO2011118453A1 (ja) | 固形製剤 | |
| CN103784414B (zh) | 一种埃索美拉唑肠溶片及其制备方法 | |
| JP2011525501A5 (enExample) | ||
| WO2005097080A1 (ja) | 経口投与剤 | |
| CN103228676A (zh) | 羟烷基纤维素 | |
| CA2967647A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| KR20110130441A (ko) | 고형 제제 | |
| JPWO2011121823A1 (ja) | 経口投与用粒子状医薬組成物 | |
| US20090202630A1 (en) | Orally disintegrating tablet compositions of ranitidine and methods of manufacture | |
| JP6417532B2 (ja) | 放出制御医薬剤形 | |
| CN101862305A (zh) | 一种盐酸氨溴索缓释微丸及制备方法 | |
| JP2009519334A (ja) | ランソプラゾール経口崩壊錠剤 | |
| US9119793B1 (en) | Gastroretentive dosage forms for doxycycline | |
| CN110461310A (zh) | 用于使用射频和有损耗的包衣粒子制备片剂的方法 |